Trials / Terminated
TerminatedNCT05520970
Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1
A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Cellid Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
The immunogenicity and safety profiles of AdCLD-CoV19-1 (5.0×10\^10 VP/dose) will be assessed for 1-dose or 2-dose regimen in SARS-CoV-2 seronegative healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AdCLD-CoV19-1 | All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region |
Timeline
- Start date
- 2022-08-19
- Primary completion
- 2022-11-08
- Completion
- 2022-11-08
- First posted
- 2022-08-30
- Last updated
- 2023-06-22
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05520970. Inclusion in this directory is not an endorsement.